BioXcel Therapeutics Inc
NASDAQ:BTAI
Balance Sheet
Balance Sheet Decomposition
BioXcel Therapeutics Inc
Current Assets | 72.1m |
Cash & Short-Term Investments | 65.2m |
Receivables | 71k |
Other Current Assets | 6.9m |
Non-Current Assets | 1.6m |
PP&E | 1.5m |
Other Non-Current Assets | 87k |
Current Liabilities | 27.3m |
Accounts Payable | 13.7m |
Accrued Liabilities | 13.4m |
Other Current Liabilities | 223k |
Non-Current Liabilities | 102.9m |
Long-Term Debt | 100.6m |
Other Non-Current Liabilities | 2.3m |
Balance Sheet
BioXcel Therapeutics Inc
Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash & Cash Equivalents |
0
|
0
|
1
|
43
|
32
|
213
|
233
|
194
|
65
|
|
Cash Equivalents |
0
|
0
|
1
|
43
|
32
|
213
|
233
|
194
|
65
|
|
Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
Other Current Assets |
0
|
0
|
0
|
1
|
2
|
4
|
4
|
7
|
5
|
|
Total Current Assets |
0
|
0
|
1
|
43
|
34
|
217
|
237
|
203
|
72
|
|
PP&E Net |
0
|
0
|
0
|
0
|
2
|
3
|
3
|
2
|
1
|
|
PP&E Gross |
0
|
0
|
0
|
0
|
2
|
3
|
3
|
2
|
1
|
|
Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
|
Other Long-Term Assets |
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Total Assets |
0
N/A
|
0
N/A
|
1
N/A
|
44
+3 007%
|
36
-16%
|
220
+504%
|
239
+9%
|
206
-14%
|
74
-64%
|
|
Liabilities | ||||||||||
Accounts Payable |
0
|
0
|
0
|
2
|
5
|
4
|
5
|
10
|
14
|
|
Accrued Liabilities |
0
|
0
|
1
|
3
|
3
|
7
|
12
|
22
|
13
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
0
|
0
|
1
|
0
|
0
|
1
|
1
|
1
|
0
|
|
Total Current Liabilities |
0
|
0
|
2
|
5
|
9
|
12
|
17
|
33
|
27
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
93
|
101
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
2
|
|
Total Liabilities |
0
N/A
|
0
+50%
|
2
+667%
|
5
+104%
|
10
+102%
|
13
+39%
|
18
+35%
|
129
+625%
|
130
+1%
|
|
Equity | ||||||||||
Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
0
|
0
|
5
|
24
|
57
|
139
|
246
|
412
|
591
|
|
Additional Paid In Capital |
0
|
0
|
4
|
63
|
84
|
346
|
467
|
488
|
534
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
0
N/A
|
0
-50%
|
1
-233%
|
39
N/A
|
27
-31%
|
207
+668%
|
222
+7%
|
77
-65%
|
57
N/A
|
|
Total Liabilities & Equity |
0
N/A
|
0
N/A
|
1
N/A
|
44
+3 007%
|
36
-16%
|
220
+504%
|
239
+9%
|
206
-14%
|
74
-64%
|
|
Shares Outstanding | ||||||||||
Common Shares Outstanding |
16
|
16
|
16
|
16
|
18
|
24
|
28
|
28
|
30
|